Abstract | Keywords | Export | Availability | Bookmark

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

In this volume, Shorter presents a revealing account of why psychiatry is 'losing ground' in the struggle to treat depression. It focuses on an unexpected villain - the FDA, the very agency charged with ensuring drug safety and effectiveness. Shorter describes how the FDA permits companies to test new products only against placebo.

Affective disorders --- Psychotropic drugs --- Psychopharmacology --- Serotonin uptake inhibitors --- Psychotropic drugs industry --- Pharmaceutical policy --- Behavioral pharmacology --- Drugs --- Chemotherapy --- Pharmacology --- Psychiatric drugs --- Psychoactive drugs --- Psychopharmaceuticals --- Drugs of abuse --- Psychotropic plants --- Disorders, Affective --- Mood disorders --- Psychology, Pathological --- Drug policy --- Drugs and state --- Pharmacy --- Pharmacy and state --- State and drugs --- State and pharmacy --- Medical policy --- Pharmaceutical industry --- 5-HT uptake inhibitors --- 5-Hydroxytryptamine uptake inhibitors --- Inhibitors, Serotonic uptake --- Reuptake inhibitors, Serotonin --- Serotonin reuptake inhibitors --- Uptake inhibitors, Serotonin --- Neurotransmitter uptake inhibitors --- History. --- Therapeutic use --- Psychotropic effects --- Government policy --- United States. --- Drug Approval --- Government Agencies --- History, 20th Century --- Mood Disorders --- Psychotropic Drugs --- history --- drug therapy